Type 2 diabetes mellitus. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Patients in the intervention group will receive two capsules of 500 milligrams of resveratrol per day in 8 weeks. Intervention 2: Patients in the control group will receive two capsule
Sponsors
Yazd University of Medical Sciences
Iran National Science Foundation
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Male and female subjects with established T2DM, who have been diagnosed for at least three months who have body mass index between 24-30 kgm2, and aged 30-60 years,
Exclusion criteria
Exclusion criteria: clinical diagnosis of any liver, kidney, cancer and Alzheimer's diseases insulin therapy; HbA1c= 8% consumption of any antioxidant supplements in the last six months history of allergic reaction to grapes; consumption of anticoagulants, fibrates and aspirin drinking red wine and alcohol history of myocardial infraction presence of stent or battery in the heart gastrointestinal ulcer pregnancy or lactation; follow the unusual diet until one month before the study; unwillingness to participation in study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proxisome proliferatore activated receptor alpha. Timepoint: Before and after intervention. Method of measurement: Gene expression.;P53 gene. Timepoint: Before and after intervention. Method of measurement: Gene expression.;P21 gene. Timepoint: Before and after intervention. Method of measurement: Gene expression.;P16 gene. Timepoint: Before and after intervention. Method of measurement: Gene expression.;Soluble Cluster of Differentiation 163. Timepoint: Before and after intervention. Method of measurement: Serum concentration using kit and The enzyme-linked immunosorbent assay method.;TNF-related weak inducer of apoptosis. Timepoint: Before and after intervention. Method of measurement: Serum concentration using kit and The enzyme-linked immunosorbent assay method.;Paraoxonase1 activity. Timepoint: Before and after intervention. Method of measurement: Serum concentration using kit and The enzyme-linked immunosorbent assay method.;Asymmetric de-methyl arginine. Timepoint: Before and after intervention. Method of measurement: Serum concentration using kit and The enzyme-linked immunosorbent assay method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Triglyceride. Timepoint: Before and after intervention. Method of measurement: Turbidometry.;Total cholesterol. Timepoint: Before and after intervention. Method of measurement: Turbidometry.;High density lipoprotein Cholesterol. Timepoint: Before and after intervention. Method of measurement: Turbidometry.;Low density lipoprotein Cholesterol. Timepoint: Before and after intervention. Method of measurement: Turbidometry.;Fasting blood glucose. Timepoint: Before and after intervention. Method of measurement: Turbidometry.;Glycated hemoglobin. Timepoint: Before and after intervention. Method of measurement: Enzymatic kit.;Fasting insulin. Timepoint: Before and after intervention. Method of measurement: The enzyme-linked immunosorbent assay.;Lipid Accumulation Product. Timepoint: Before and after intervention. Method of measurement: Formula.;Visceral adiposity index. Timepoint: Before and after intervention. Method of measurement: Formula.;Castelli 1 index. Timepoint: Before and after intervention. Method of measurement: Formula.;Castelli 2 index. Timepoint: Before and after intervention. Method of measurement: Formula.;Atherogenic Coefficient. Timepoint: Before and after intervention. Method of measurement: Formula. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact?Shima Abdollahi
Yazd University of Medical Sciences
Outcome results
None listed